|
VIEWPOINT
Centers for Disease Control and Prevention Guideline for Prescribing Opioids, 2022—Need for Integrating Dosing Benchmarks With Shared Decision-Making
Mark D. Sullivan, MD, PhD; Jeffrey A. Linder, MD, MPH; Jason N. Doctor, PhD
Editor's Note: Opioid Dosing by Primary Care Professionals—A Call for Humility; Mitchell H. Katz, MD; Deborah Grady, MD
ORIGINAL INVESTIGATION
Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial
Ana Maria Copaescu, MD; Sara Vogrin, MBiostat; Fiona James, BBiomedSci; et al.
INVITED COMMENTARY
Just-in-Time Digital Health Interventions—Start of a New Era With Much More to Do
Raman Khanna, MD, MAS; Andrew Auerbach, MD, MPH
EDITOR'S NOTE
Opioid Dosing by Primary Care Professionals—A Call for Humility
Mitchell H. Katz, MD; Deborah Grady, MD
Evolving Methods to Assess Chatbot Performance in Health Sciences Research
Eric Ward, MD; Cary Gross, MD
REVIEW
Assessment of US Food and Drug Administration–Approved Digital Medical Devices for Just-in-Time Interventions: A Systematic Review
Ngan Thi Thuy Phi, MSc; Theodora Oikonomidi, MSc, PhD; Philippe Ravaud, MD, MSc, HDR, PhD; et al.
Earn CME credit
RESEARCH LETTER
Comparison of History of Present Illness Summaries Generated by a Chatbot and Senior Internal Medicine Residents
Ashwin Nayak, MD, MS; Matthew S. Alkaitis, MD, PhD; Kristen Nayak, MD; et al.
Editor's Note: Evolving Methods to Assess Chatbot Performance in Health Sciences Research; Eric Ward, MD; Cary Gross, MD
Chatbot vs Medical Student Performance on Free-Response Clinical Reasoning Examinations
Eric Strong, MD; Alicia DiGiammarino, MS; Yingjie Weng, MHS; et al.
Editor's Note: Evolving Methods to Assess Chatbot Performance in Health Sciences Research ; Eric Ward, MD; Cary Gross, MD
CHALLENGES IN CLINICAL ELECTROCARDIOGRAPHY
Ventricular Arrest With a Duration of 23.8 Seconds
Zhongzheng Zhou, MD; Yi Long, MD; Yong Li, MD
Earn CME credit
BREAKING: DONANEMAB FOR ALZHEIMER DISEASE
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
John R. Sims, MD; Jennifer A. Zimmer, MD; Cynthia D. Evans, PhD; et al.
Editorial: Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed? ; Jennifer J. Manly, PhD; Kacie D. Deters, PhD
Editorial: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease; Gil D. Rabinovici, MD; Renaud La Joie, PhD
Editorial: Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy; Meredith B. Rosenthal, PhD
Editorial: Ushering in a New Era of Alzheimer Disease Therapy; Eric W. Widera, MD; Sharon A. Brangman, MD; Nathaniel A. Chin, MD
COMMENT & RESPONSE
Less Is More
Preoperative Medical Consultation—Questioning a Long-Standing Practice
Vasu Sareen, MD; Daniel Ho, MD
Preoperative Medical Consultation—Questioning a Long-Standing Practice
Nirvik Pal, MBBS, MD; Mark Nelson, MD; John Butterworth, MD
Less Is More
Preoperative Medical Consultation—Questioning a Long-Standing Practice—In Reply
Weiwei Beckerleg, MD, MPH; Daniel I. McIsaac, MD, MPH
|
